CYGX: NEWS - 500 Beiträge pro Seite

[crashpoet]

kam nachbörslich:

CytoGenix synDNA(TM) HIV Vaccine Shows Robust Cellular Immune Response in Monkeys



HOUSTON--(BUSINESS WIRE)--

CytoGenix (OTCBB:CYGX) has demonstrated that a synDNA(TM) vaccine against human immunodeficiency virus (HIV) has activity in monkeys. The study, conducted by Drs. Yin Chen and Frederic Kendirgi at CytoGenix in collaboration with Lauren Hirao and Dr. David Weiner of the University of Pennsylvania, demonstrated that rhesus monkeys injected with a synDNA(TM) HIV vaccine mounted a significant cellular immune response. The study involved monkeys treated with a synDNA(TM) vaccine targeting two key viral proteins (gag and env) with interleukin-15 as an adjuvant.

"This observation, the first evidence of activity for a synDNA(TM) vaccine in non-human primates, is encouraging in that it shows that the synDNA(TM) vaccine is as effective as the DNA plasmid-based vaccine expressing the same antigen. The advantages of using DNA vaccines can be significantly extended using synDNA(TM) constructs and warrants further study to determine if the response is sufficient to protect against HIV infection," stated David B. Weiner, Ph.D., an expert in DNA vaccination and a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine.

The World Health Organization has estimated that nearly 40 million people worldwide are HIV positive with over one half of those infected residing in sub-Saharan Africa. The incidence of newly diagnosed infections has skyrocketed in parts of Eastern Europe and Central Asia with infection rates increasing by more than 50% in some regions since 2004. In the United States, approximately 1.2 million people were reported to be infected with HIV in 2005 and only seven other countries in the world have a higher number of affected citizens.

"Demonstration of the bioactivity of a synDNA(TM) vaccine for HIV in non-human primates is a tremendous step forward for CytoGenix," commented Dr. Malcolm Skolnick, President & CEO of CytoGenix, Inc. "This experiment highlights the potential of the application of synDNA(TM) to the field of DNA vaccines as well as the use of DNA therapeutic drugs," continued Dr. Skolnick.

Dr. Yin Chen, Chief Scientific Officer at CytoGenix, comments, "The use of enzymatically synthesized, bacteria free DNA to achieve significant biological activity is a significant advance for the field of vaccines and gene therapies. CytoGenix\'s synDNA(TM) products present a number of advantages over DNA plasmids produced by bacterial fermentation. The synDNA(TM) constructs avoid the use of antibiotic resistance genes and other bacterial sequences, can be rapidly produced and are more cost effective to produce. These are major advantages in developing vaccines for a wide range of applications including pandemic and bioterror threats."

About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has issued patents on its ssDNA expression technology in the US, China and nine European countries with over 41 additional international or US pending patent applications on variations of this and the synDNA(TM) technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company\'s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Source: CytoGenix, Inc.

[ketsie]

Antwort auf Beitrag Nr.: 26.118.168 von crashpoet am 12.12.06 09:04:14

kurs reagiert ja jetzt erstaunlich positiv ... mal sehen, ob es wieder über den euro geht ...

[ketsie]

tut sich hier was, oder ist es nur eine korrektur

[ketsie]

CytoGenix Adds DNA Purification Expert to Scientific Advisory Board
Houston, TX (April 2, 2007) CytoGenix, Inc. (CYGX.OB) announced today that Richard Willson, Ph.D. has agreed to join the Company's Scientific Advisory Board. Dr. Wilson is a Professor in the Department of Chemical & Biomolecular Engineering at the University of Houston. Professor Willson brings to the SAB a vast knowledge base in the area of biomolecular recognition as it applies to separation technology and molecular diagnostics. More information on his work and accomplishments may be found at www.chee.uh.edu/faculty/willson.

Malcolm Skolnick, Chairman and CEO of CytoGenix stated "Dr. Willson is capable of making an immediate, substantive contribution to the Company's goal of commercialization of synDNA™. Dr. Willson's expertise in DNA purification strategies and nanostructured adsorbents will assist CytoGenix in addressing key issues in the scale-up technology necessary for commercial-scale synDNA™ production. We are delighted to have Dr. Willson join our SAB."

Dr. Willson stated, "I am excited to be working with CytoGenix to bring synDNA™ into the realm of commercial scale manufacturing. This novel drug substance represents an opportunity to develop many new products with distinct advantages over existing plasmid-based technology."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNATM production and ssDNA expression technologies. The company has developed a breakthrough cell-free process for large-scale production of high purity DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside a cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Contact: Malcolm Skolnick [phone].

[wayne99]

Starke News heute !!

Press Release Source: CytoGenix, Inc.


CytoGenix Announces Successful Testing of synDNA(TM) Vaccine for Avian Influenza Virus
Wednesday April 4, 7:00 am ET


HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (CYGX.OB) announced today that it has successfully completed an important pilot study with a novel synDNA(TM) vaccine designed for humans (therapeutic) and intended to protect against the avian (H5N1) influenza virus. The study clearly demonstrated a robust protective effect in mice treated with the Company's synDNA(TM) vaccine whereas all the untreated control animals died after both groups were challenged with a highly virulent strain of avian influenza virus (Vietnam/1203/04). The lethal challenge testing was conducted by recognized collaborators in the field under a sponsored research agreement with the Company.
ADVERTISEMENT

The complete results from this study and related tests of synDNA(TM) vaccines will be presented at the 2007 DNA Vaccine conference to be held 23-25 May 2007 in Malaga, Spain.

Dr. Yin Chen, Chief Scientific Officer, stated, "This novel DNA vaccine was produced using a unique combination of novel gene sequences and our proprietary synDNA(TM) production technology. We are extremely excited about this initial robust response in an animal challenge model."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.



Contact:
CytoGenix, Inc., Houston
Media Contact:
Pam Schertz, 713-789-0070

--------------------------------------------------------------------------------
Source: CytoGenix, Inc.